Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Heni, Martin ^a   Hennenlotter, Jörg ^a   Scharpf, Marcus ^b   Lutz, Stefan Z ^a   Schwentner, Christian ^a   Todenhöfer, Tilman ^a   Schilling, David ^a   Kühs, Ursula ^a   Gerber, Valentina ^a   Machicao, Fausto ^a   Staiger, Harald ^a   Häring, Hans Ulrich ^a   Stenzl, Arnulf ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; INSULIN RECEPTOR; INSULIN RECEPTOR A; INSULIN RECEPTOR B; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; SOMATOMEDIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE CANCER; PROSTATE CANCER FOCI; PROSTATE TUMOR; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

AGED; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84870900365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050953     Document Type: Article

References (27)

1. Renehan A, Smith U, Kirkman MS, (2010) Linking diabetes and cancer: a consensus on complexity. Lancet 375: 2201-2202 doi:10.1016/S0140-6736(10)60706-4.
2. Müssig K, Staiger H, Kantartzis K, Fritsche A, Kanz L, et al. (2011) Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism? Diabet Med 28: 276-286 doi:10.1111/j.1464-5491.2010.03132.x.
3. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685 doi:10.2337/dc10-0666.
4. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, et al. (2011) Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 14: 326-331 doi:10.1038/pcan.2011.28.
5. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E, (2008) Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19: 703-710 doi:10.1007/s10552-008-9133-x.
6. Grossmann M, (2011) Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 96: 2341-2353 doi:10.1210/jc.2011-0118.
7. Currie CJ, Poole CD, Jenkins-Jones S, Gale EAM, Johnson JA, et al. (2012) Mortality After Incident Cancer in People With and Without Type 2 Diabetes: Impact of metformin on survival. Diabetes Care 35: 299-304 doi:10.2337/dc11-1313.
8. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R, (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623 doi:10.1210/er.2008-0047.
9. Merseburger AS, Hennenlotter J, Simon P, Müller CC, Kühs U, et al. (2006) Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 16: 79-83.
10. Waalkes S, Simon P, Hennenlotter J, Knapp J, Tezval H, et al. (2010) Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue. Oncol Rep 23: 1257-1260.
11. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, et al. (2009) Insulin receptor expression by human prostate cancers. Prostate 69: 33-40 doi:10.1002/pros.20852.
12. White MF, (1998) The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182: 3-11.
13. Taniguchi CM, Emanuelli B, Kahn CR, (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96 doi:10.1038/nrm1837.
14. White MF, (2002) IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-422 doi:10.1152/ajpendo.00514.2001.
15. Shaw LM, (2011) The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 10: 1750-1756.
16. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, et al. (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5: 45 doi:10.1186/1471-2407-5-45.
17. Macri E, Loda M, (1998) Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev 17: 337-344.
18. Heni M, Hennige AM, Peter A, Siegel-Axel D, Ordelheide A-M, et al. (2011) Insulin promotes glycogen storage and cell proliferation in primary human astrocytes. PLoS ONE 6: e21594 doi:10.1371/journal.pone.0021594.
19. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr, (1997) p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158: 131-137 doi:10.1097/00005392-199707000-00040.
20. Gallagher EJ, LeRoith D, (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21: 610-618 doi:10.1016/j.tem.2010.06.007.
21. Gibson SL, Ma Z, Shaw LM, (2007) Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 6: 631-637.
22. Ma Z, Gibson SL, Byrne MA, Zhang J, White MF, et al. (2006) Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol 26: 9338-9351 doi:10.1128/MCB.01032-06.
23. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF, et al. (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942-2950.
24. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230.
25. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, et al. (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12: 6626-6636 doi:10.1158/1078-0432.CCR-06-0467.
26. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R, (2001) Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 17: 363-373.
27. Hribal ML, Perego L, Lovari S, Andreozzi F, Menghini R, et al. (2003) Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. FASEB J 17: 1340-1342 doi:10.1096/fj.02-0685fje.